AI Engines For more Details: Perplexity Kagi Labs You
Peripheral Vascular Disease: Isoxsuprine hydrochloride is often prescribed to individuals with peripheral vascular disease (PVD), a condition characterized by reduced blood flow to the limbs due to narrowed or blocked blood vessels. By dilating peripheral arteries and improving blood circulation, isoxsuprine helps alleviate symptoms such as leg pain, cramping, and intermittent claudication.
Raynaud's Phenomenon: Isoxsuprine may be used to manage Raynaud's phenomenon, a condition characterized by episodes of reduced blood flow to the fingers and toes, leading to color changes (white, blue, or red) and discomfort. By dilating blood vessels, isoxsuprine can help improve blood circulation in affected areas and reduce the frequency and severity of Raynaud's attacks.
Preterm Labor: Isoxsuprine hydrochloride is sometimes used off-label to suppress uterine contractions and delay preterm labor. By relaxing the uterine smooth muscles and reducing uterine activity, isoxsuprine may help prolong pregnancy and reduce the risk of premature birth in women at risk of preterm labor.
Improvement of Cerebral Blood Flow: Isoxsuprine's vasodilatory effects may also be beneficial in improving cerebral blood flow in certain conditions, such as cerebral vascular insufficiency or post-stroke recovery. By dilating cerebral blood vessels, isoxsuprine can enhance oxygen and nutrient delivery to the brain, potentially improving neurological function.
Enhancement of Coronary Blood Flow: In some cases, isoxsuprine hydrochloride may be used to improve coronary blood flow in individuals with coronary artery disease (CAD) or angina pectoris. By dilating coronary arteries, isoxsuprine can increase oxygen supply to the heart muscle, reducing the frequency and severity of anginal episodes.
Vasospastic Disorders: Isoxsuprine's vasodilatory properties make it potentially beneficial in the management of vasospastic disorders, such as Prinzmetal's angina, where abnormal constriction of blood vessels leads to reduced blood flow to certain organs or tissues. Isoxsuprine may help prevent vasospasm and alleviate associated symptoms.
Enhanced Blood Flow in Renal Artery Stenosis: Isoxsuprine may be used to improve blood flow in the renal arteries in individuals with renal artery stenosis, a condition characterized by narrowing of the arteries supplying the kidneys. By dilating renal blood vessels, isoxsuprine can help improve renal perfusion and function.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.9 | 0.2 | 3.5 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
Allergic Rhinitis (Hay Fever) | 0.8 | 0.8 | |
Allergies | 1.5 | 0.6 | 1.5 |
Allergy to milk products | 1.1 | 0.5 | 1.2 |
Alzheimer's disease | 2.7 | 1.6 | 0.69 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 1.2 | 0.67 |
Ankylosing spondylitis | 1.4 | 0.8 | 0.75 |
Anorexia Nervosa | 0.1 | 0.7 | -6 |
Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
Asthma | 0.5 | 0.9 | -0.8 |
Atherosclerosis | 0.5 | 0.5 | 0 |
Atrial fibrillation | 0.6 | 0.7 | -0.17 |
Autism | 3.7 | 3.8 | -0.03 |
Barrett esophagus cancer | 0.5 | 0.2 | 1.5 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 0.6 | 0.3 | 1 |
Brain Trauma | 0.3 | -0.3 | |
Carcinoma | 1 | 0.2 | 4 |
Celiac Disease | 1.9 | 0.7 | 1.71 |
Cerebral Palsy | 0.5 | 0.3 | 0.67 |
Chronic Fatigue Syndrome | 1.4 | 1.3 | 0.08 |
Chronic Kidney Disease | 0.8 | 0.4 | 1 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0.4 | 2.25 |
Chronic Urticaria (Hives) | 1.5 | 1 | 0.5 |
Coagulation / Micro clot triggering bacteria | 1.4 | 0.3 | 3.67 |
Colorectal Cancer | 3.7 | 3.7 | |
Constipation | 1.5 | 0.2 | 6.5 |
Coronary artery disease | 0 | 0 | |
COVID-19 | 3.6 | 3.2 | 0.13 |
Crohn's Disease | 4.3 | 2.3 | 0.87 |
cystic fibrosis | 1.2 | 0.3 | 3 |
deep vein thrombosis | 1.2 | 0.3 | 3 |
Depression | 4.3 | 2.1 | 1.05 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.4 | 1.1 | -1.75 |
Endometriosis | 1.6 | 0.2 | 7 |
Eosinophilic Esophagitis | 0.5 | 0 | 0 |
Epilepsy | 1.9 | 1 | 0.9 |
Fibromyalgia | 0.6 | 0.6 | 0 |
Functional constipation / chronic idiopathic constipation | 3.1 | 1.2 | 1.58 |
gallstone disease (gsd) | 0.7 | 0.6 | 0.17 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.2 | 8 |
Generalized anxiety disorder | 1.6 | 0.3 | 4.33 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.2 | 0.2 | 0 |
Halitosis | 0.6 | 0.2 | 2 |
Hashimoto's thyroiditis | 0.5 | 0.1 | 4 |
Hidradenitis Suppurativa | 0.6 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 1.7 | |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.4 | -1 |
hyperglycemia | 0.4 | 0.8 | -1 |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
hypertension (High Blood Pressure | 1 | 1.5 | -0.5 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1 | -1 | |
Inflammatory Bowel Disease | 2.4 | 1.9 | 0.26 |
Insomnia | 0.3 | 0.5 | -0.67 |
Intelligence | 0.4 | 0.1 | 3 |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 2.3 | 2 | 0.15 |
Liver Cirrhosis | 1.8 | 0.8 | 1.25 |
Long COVID | 2.9 | 1.7 | 0.71 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.5 | 0.4 | 0.25 |
ME/CFS with IBS | 0.3 | 0.1 | 2 |
ME/CFS without IBS | 1 | 0.1 | 9 |
Metabolic Syndrome | 3.4 | 3.7 | -0.09 |
Mood Disorders | 5.1 | 2.2 | 1.32 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
Multiple Sclerosis | 2.5 | 2.2 | 0.14 |
Multiple system atrophy (MSA) | 1.4 | 1.4 | |
Neuropathy (all types) | 0.4 | 0.4 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 0.8 | 0 |
Obesity | 1.8 | 1.6 | 0.13 |
obsessive-compulsive disorder | 3.4 | 0.6 | 4.67 |
Osteoarthritis | 0.8 | 0.8 | |
Osteoporosis | 0.9 | 0.5 | 0.8 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 1.8 | 2 | -0.11 |
Polycystic ovary syndrome | 1.6 | 0.5 | 2.2 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
primary biliary cholangitis | 0.2 | -0.2 | |
Psoriasis | 1.9 | 0.9 | 1.11 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.5 | 0.67 |
Rosacea | 0.3 | -0.3 | |
Schizophrenia | 1.8 | 0.3 | 5 |
scoliosis | 0.5 | -0.5 | |
Sjögren syndrome | 0.8 | 0.4 | 1 |
Sleep Apnea | 0.5 | 0.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
Stress / posttraumatic stress disorder | 2 | 1 | 1 |
Systemic Lupus Erythematosus | 2 | 0.4 | 4 |
Tic Disorder | 0.8 | 0.1 | 7 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 1.9 | 1.5 | 0.27 |
Type 2 Diabetes | 4 | 4.2 | -0.05 |
Ulcerative colitis | 1.7 | 2.2 | -0.29 |
Unhealthy Ageing | 3.2 | 0.4 | 7 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.